|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 25.82 USD | +3.57% |
|
-0.84% | +12.26% |
| 08-05 | Ultragenyx Pharmaceutical Q2 Loss Narrows as Revenue Rises; 2026 Revenue Guidance Reaffirmed | MT |
| 08-04 | Ultragenyx Pharmaceutical Inc., Q2 2026 Earnings Call, Aug 04, 2026 |
Chart: Technical Analysis
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Bearish | Neutral | Neutral |
| Resistance | 30.68 | 35.87 | 36.38 |
| Spread/Res. | -15.84% | -28.02% | -29.03% |
| Spread/Supp. | +3.65% | +39.57% | +33.23% |
| Support | 24.91 | 18.5 | 19.38 |
MarketScreener's Technical Analysis Ratings
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Stocks
- RARE Stock
- Charts Ultragenyx Pharmaceutical Inc.
Select your edition
All financial news and data tailored to specific country editions
